Previous 10 | Next 10 |
Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete response rate after a single dose of AUTO1 LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -...
LONDON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in the following investor conferences in September: Dr. C...
Autolus Therapeutics plc (AUTL) Q2 2019 Earnings Conference Call August 08, 2019 8:30 AM ET Company Participants Silvia Taylor - Vice President, Corporate Affairs & Communication Christian Itin - Chairman & Chief Executive Officer Andrew Oakley - Chief Financial Officer ...
Autolus Therapeutics (NASDAQ: AUTL ): Q2 GAAP EPS of -$0.65 beats by $0.11 . More news on: Autolus Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...
LONDON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its financial and operational results for the second quarter ended June 30, 2019. O...
LONDON, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2019 financial results and operational high...
LONDON, May 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in the following investor conferences in June: ...
Autolus Therapeutics PLC (AUTL) Q1 2019 Earnings Conference Call May 14, 2019, 08:30 ET Company Participants Silvia Taylor - VP, Corporate Affairs and Communication Christian Itin - Chairman & CEO Andrew Oakley - CFO & SVP Conference Call Participants Biren Amin - J...
Autolus Therapeutics (NASDAQ: AUTL ): Q1 GAAP EPS of -$0.69 misses by $0.07 . More news on: Autolus Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...
LONDON, May 14, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its financial and operational results for the first quarter ended March 31, 2019. Key...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights befo...
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...